Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

DOI Web Site Web Site 1 Citations

Journal

  • The Lancet

    The Lancet 402 (10408), 1133-1146, 2023-09

    Elsevier BV

Citations (1)*help

See more

Report a problem

Back to top